Navigation Links
Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008
Date:10/13/2008

WALTHAM, Mass., Oct. 13 /PRNewswire/ -- Proteon Therapeutics is presenting new data today representing an important preclinical demonstration of the potential of PRT-201 to enhance outcomes in patients suffering from lower limb peripheral arterial disease (PAD). The presentation, entitled, "Local Catheter-Directed Elastase Therapy: A Novel Approach to Vessel Dilation and Restenosis," is being made at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. The new findings are being presented by F. Nicholas Franano, M.D., Chief Scientific Officer of Proteon Therapeutics.

"These preliminary non-clinical results showing vessel dilation with PRT-201 are very exciting," said Timothy P. Noyes, the Company's President and CEO. "We believe that local catheter delivery of PRT-201 immediately following balloon angioplasty procedures could potentially reduce the incidence of restenosis in PAD."

About Peripheral Arterial Disease

Peripheral artery disease, or PAD, is characterized by fatty plaque build-up in the arteries of the legs, which leads to poor blood flow and circulation. According to the American Heart Association, PAD affects eight million Americans and is a significant cause of both morbidity and death. Patients with PAD may experience muscle pain during walking, have wounds and ulcers that are slow to heal or, in the most severe cases, require amputation of the legs. Current interventional procedures, such as balloon angioplasty, are inadequate due to high rates of restenosis that restricts blood flow following treatment of the diseased vessel segments.

About Proteon Therapeutics

Proteon Therapeutics, Inc., is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases. The company is leveraging a unique understanding of tissue remodeling to develop a pipeline of proprietary pharmaceuticals. The company is headquartered in Waltham, Mass., and has research facilities in Kansas City, Mo. For additional information, please visit http://www.proteontherapeutics.com.


'/>"/>
SOURCE Proteon Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
2. Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007
3. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
4. Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
5. National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc.
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... ... Biova, LLC., the leader in water soluble egg membrane ingredients, announced today ... bring a wealth of scientific experience in the food, beverage, nutrition and dietary supplement ... of four major global companies in the last 4 decades. He has a ...
(Date:6/22/2017)... , ... June 21, 2017 , ... ... and hiring top executive talent in the life sciences industry, today announces a ... company. The partnership takes full advantage of Beaker’s expertise in executive recruitment ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... RegMedNet has produced a Spotlight series on “Cell Therapy ... and perspectives by leading experts on the unique regulatory challenges of stem cell ...
(Date:6/20/2017)... Hill, CT (PRWEB) , ... June 20, 2017 ... ... support, today announced that the CTNext board of directors has formed a Higher ... by a working group composed of institution presidents and other high-ranking representatives from ...
Breaking Biology Technology:
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:3/30/2017)... HONG KONG , March 30, 2017 ... developed a system for three-dimensional (3D) fingerprint identification by adopting ground ... technology into a new realm of speed and accuracy for use ... applications at an affordable cost. ... ...
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
Breaking Biology News(10 mins):